Investment Companies Roundup Kindly sponsored by Baillie Gifford New research Over September, we published notes on India Capital Growth, Jupiter Emerging & Frontier, International Biotechnology Trust, JPMorgan Russian Securities, Civitas Social Housing, Montanaro European Smaller Companies and JLEN Environmental Assets. We also launched a monthly real estate roundup, beginning with reviews of August and September. In […]
Top 100 Funds 2019: Specialist equity funds By Leonora Walters If you have a large portfolio and a higher risk appetite, you could consider adding a small allocation to some specialist equities funds focused on a particular area that could benefit from high growth… NEW ENTRANT:Polar Capital Global Insurance(IE00B61MW553): Insurance company equities can be a good […]
Targeting full dividend cover Civitas Social Housing (CSH) has secured a new £60m debt facility that it will use to buy new properties. This will increase its rental income and move CSH very close to full dividend cover. CSH has the option to extend the new loan by another £40m and is also in advanced […]
Targeting full dividend cover Civitas Social Housing (CSH) has secured a new £60m debt facility that it will use to buy new properties. This will increase its rental income and move CSH very close to full dividend cover. CSH has the option to extend the loan by another £40m and is also in advanced negotiations […]
Acadia stock surges 65% on positive trial result in dementia psychosis – US biotech Acadia Pharmaceuticals (Nasdaq: ACAD) saw its stock jump 65% today on the back of a positive result in its “Harmony” Phase III study of Nuplazid (pimavanserin) for dementia-related psychosis. The company reported that the study met its primary endpoint, demonstrating a […]
BMS claims still on track to close Celgene deal by early 2020 – Bristol-Myers Squibb (BMS) has confirmed that it remains on track to close its proposed $74bn acquisition of the US biotech giant Celgene by the end 2019 or in early 2020, even though this is now dependent on securing a separate deal to […]
Trust favourite Sage to test ‘217 in treatment resistant depression – US biotech Sage Therapeutics announced plans to advance its lead development candidate, SAGE-217 (zuranolone) into a Phase III trial for treatment-resistant depression (TRD). The drug is already in Phase III for major depressive disorder (MDD) and has completed – successfully – a Phase III […]
Acadia falls on negative trial result in schizophrenia – US biotech Acadia Pharmaceuticals (Nasdaq: ACAD) saw its stock fall by 15% today on the back of a negative top-line result from its 396-patient “Enhance” Phase III study of Nuplazid (pimavanserin) in treatment resistant schizophrenia. The company, which is a mid-size holding of the UK’s International Biotechnology […]
Trust favourite Gilead expands R&D deal with Galapagos – US biotech giant Gilead Sciences (NASDAQ: GILD) has entered into a ten-year R&D collaboration with Galapagos (Euronext/NASDAQ: GLPG) covering rights to the Belgium group’s entire development portfolio. The transformative deal includes a $3.95bn upfront payment – a new record in the industry – as well as $1.1bn in […]
Morphosys receives milestone as GSK advances RA antibody – German biotech MorphoSys (NASDAQ: MOR), a holding of International Biotechnology Trust (IBT), has received a €22m milestone payment from its licensing partner GlaxoSmithKline (GSK) in connection with the start of a Phase III trial programme with otilimab (formerly MOR103/GSK3196165) in rheumatoid arthritis (RA). GSK will conduct four […]
